PMGC Holdings (ELAB) Fair Value & Analysis
Healthcare · US · Market cap $6.3M
PMGC Holdings
ELAB · US
Fair value as of: Jul 15, 2026
From 1 valuation models · updated today
Share price −23.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.06 – $216.72 · fair‑value band $0.2295 – $0.4335 · the $1.12 price screens above the $0.3400 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PMGC Holdings (ELAB) currently trades at $1.12, while our model-based Fair Value estimate is $0.3400 — implying the stock looks roughly 69.6% overvalued today. We read business quality at 17/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $1.3M. Revenue declined 45.8% year over year. The balance sheet holds a net cash position of $2.8M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.2295 (bear case) to $0.4335 (bull case); at $1.12, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at -70%, ELAB screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PMGC Holdings reported revenue of $590K in FY2025 versus $827 in FY2021, a compound +416.8%/yr. Reported net income was −$7.7M in FY2025.
Is ELAB fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PMGC Holdings (ELAB) undervalued?
What is the fair value of ELAB?
What is the quality score of ELAB?
What is the revenue of PMGC Holdings (ELAB)?
What is the net profit margin of ELAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full PMGC Holdings analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.